FDA loses oversight of diagnostic devices in new 'innovation' bill

What it does

This bill amends federal drug and device law to exempt non-invasive diagnostic devices—those that do not penetrate skin, are not implanted, cause only temporary compression or temperature changes, and do not use ionizing radiation—from FDA regulation as medical devices. The exemption removes these devices from the pre-market approval and post-market oversight requirements that currently apply to diagnostic devices, allowing manufacturers to bring them to market without FDA clearance.

Why we flagged it

The bill's operative mechanism is a categorical exemption from FDA device regulation. Despite the 'innovation acceleration' framing, the core function is to remove pre-market safety review and post-market oversight for a class of diagnostic devices, shifting regulatory burden from manufacturers to end-users.

What the text implies

• The definition of 'non-invasive' excludes ionizing radiation but does not exclude other forms of radiation (microwave, RF, ultrasound), potentially allowing unvetted electromagnetic diagnostic devices to market.
• Diagnostic devices exempt from FDA oversight may still make medical claims (e.g., 'detects disease X') without evidence of accuracy, creating a market for unvalidated diagnostics that could delay treatment or cause patient harm.
• The exemption applies to ALL non-invasive diagnostic devices meeting the definition—including wearables, at-home tests, and AI-powered analysis tools—with no tiering by risk or clinical significance.
• Removal of post-market reporting requirements means adverse events (false negatives, device failures, patient injuries) will not be systematically tracked or reported to FDA, preventing identification of safety signals.
• State and local health departments may lack authority or resources to fill the FDA oversight gap, leaving consumers in a regulatory vacuum.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Consumers lose FDA pre-market safety and effectiveness review for an entire category of diagnostic devices. While the definition of 'non-invasive' is narrow on its face, diagnostic devices—even non-invasive ones—can produce false results, mislead patients, delay treatment, or cause harm through misdiagnosis. Removing FDA oversight shifts risk from manufacturers to patients and healthcare providers.

Who stands to gain

• diagnostic device manufacturers
• wearable technology companies
• at-home testing kit producers
• AI/software diagnostic platforms

Named in the bill

FDA, Federal Food, Drug, and Cosmetic Act, Section 201(h), Section 520(o), diagnostic device manufacturers

Where it stands

• Jan 3, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 3, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.